文献速递糖尿病

达塞曲普降低冠心病患者新发糖尿病风险

Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease.
PubMed 文献 · Diabetes Care · 2020-03-06

在dal-OUTCOMES试验中,15,871例近期急性冠脉综合征患者随机接受达塞曲普600 mg每日一次或安慰剂治疗。基线无糖尿病的10,645例患者中,中位随访30个月,达塞曲普组新发糖尿病403/5,326例(7.6%),安慰剂组516/5,319例(9.7%),绝对风险降低2.1%,风险比0.77(95%CI 0.68-0.88;P<0.001),需治疗40例3年预防1例新发糖尿病。

要点

  • 达塞曲普组新发糖尿病7.6%,安慰剂组9.7%,绝对风险降低2.1%。
  • 风险比0.77(95%CI 0.68-0.88;P<0.001),需治疗40例3年预防1例。
  • 基线糖尿病前期者需治疗25例3年预防1例新发糖尿病。

核心结论

  • 在近期急性冠脉综合征患者中,新发糖尿病常见,达塞曲普治疗可大幅降低其发生。

研究设计与样本

  • dal-OUTCOMES试验:15,871例近期急性冠脉综合征患者随机接受达塞曲普600 mg每日一次或安慰剂,始于急性冠脉综合征后4-12周。
  • 基线无糖尿病定义为无糖尿病史、未使用降糖药且血红蛋白A1c和血清葡萄糖低于诊断阈值,共10,645例(占试验队列67%)。

主要发现

  • 中位随访30个月,达塞曲普组新发糖尿病403/5,326例(7.6%),安慰剂组516/5,319例(9.7%)。
  • 绝对风险降低2.1%,风险比0.77(95%CI 0.68-0.88;P<0.001),需治疗40例3年预防1例新发糖尿病。
  • 基线糖尿病前期者需治疗25例3年预防1例新发糖尿病。
  • 达塞曲普减少从血糖正常进展为糖尿病前期的患者数,并增加从糖尿病逆转为无糖尿病的患者数。

关键数值与推荐

  • 新发糖尿病定义为任何糖尿病相关不良事件、新使用降糖药、血红蛋白A1c≥6.5%,或至少两次血清葡萄糖≥7.0 mmol/L(空腹)或≥11.1 mmol/L(随机)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Incident type 2 diabetes is common among patients with recent acute coronary syndrome and is associated with an adverse prognosis. Some data suggest that cholesteryl ester transfer protein (CETP) inhibitors reduce incident type 2 diabetes. We compared the effect of treatment with the CETP inhibitor dalcetrapib or placebo on incident diabetes in patients with recent acute coronary syndrome. RESEARCH DESIGN AND METHODS: In the dal-OUTCOMES trial, 15,871 patients were randomly assigned to treatment with dalcetrapib 600 mg daily or placebo, beginning 4-12 weeks after an acute coronary syndrome. Absence of diabetes at baseline was based on medical history, no use of antihyperglycemic medication, and hemoglobin A1c and serum glucose levels below diagnostic thresholds. Among these patients, incident diabetes after randomization was defined by any diabetes-related adverse event, new use of antihyperglycemic medication, hemoglobin A1c ≥6.5%, or a combination of at least two measurements of serum glucose ≥7.0 mmol/L (fasting) or ≥11.1 mmol/L (random). RESULTS: At baseline, 10,645 patients (67% of the trial cohort) did not have diabetes. During a median follow-up of 30 months, incident diabetes was identified in 403 of 5,326 patients (7.6%) assigned to dalcetrapib and in 516 of 5,319 (9.7%) assigned to placebo, corresponding to absolute risk reduction of 2.1%, hazard ratio of 0.77 (95% CI 0.68-0.88; P < 0.001), and a need to treat 40 patients for 3 years to prevent 1 incident case of diabetes. Considering only those with prediabetes at baseline, the number needed to treat for 3 years to prevent 1 incident case of diabetes was 25. Dalcetrapib also decreased the number of patients who progressed from normoglycemia to prediabetes and increased the number who regressed from diabetes to no diabetes. CONCLUSIONS: In patients with a recent acute coronary syndrome, incident diabetes is common and is reduced substantially by treatment with dalcetrapib.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Schwartz GG, Leiter LA, Ballantyne CM, et al. Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. Diabetes Care. 2020. PMID: 32144166. doi:10.2337/dc19-2204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。